On November 11, 2021, TherapeuticsMD, Inc. announced that Mr. Hugh O?Dowd, the Company?s current President, will succeed Mr. Robert G. Finizio, the Company?s Co-founder and current Chief Executive Officer, as the Company?s Chief Executive Officer effective on or before December 31, 2021. Mr. O?Dowd will also be appointed to the Company?s Board of Directors. Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors. Mr. O?Dowd previously served as President, Chief Executive Officer, and member of the Board of Directors of Neon Therapeutics, Inc., a clinical-state immuno-oncology company until its acquisition by BioNTech SE in May 2020. Prior to Neon Therapeutics, Mr. O?Dowd spent more than 20 years in a variety of senior leadership roles at Novartis Pharmaceuticals Corporation, where he served as Country President and General Manager of the United Kingdom and Ireland, Senior Vice President and Chief Commercial Officer of Novartis Oncology, and Vice President, Latin America Region Head for the Oncology business unit.